Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Circulating Mirna and Circulating Tumor Dna Application As Liquid Biopsy Markers in Gastric Cancer Publisher Pubmed



Shaker F1, 2 ; Razi S2, 3 ; Rezaei N3, 4, 5
Authors

Source: Clinical Biochemistry Published:2024


Abstract

Liquid biopsy has been investigated as a novel method to overcome the numerous challenges in gastric cancer (GC) management. This non-invasive, feasible, and easy-to-repeat method has been shown to be cost-effective and capable of increasing diagnostic sensitivity and prognostic assessment. Additionally, it is potentially accurate to aid decision-making and personalized treatment planning. MicroRNA (miRNA) and circulating tumor DNA (ctDNA) markers can enhance GC management in various aspects, including diagnosis (mainly earlier diagnosis and the ability to perform population-based screening), prognosis (more precise stratification of prognosis), and treatment (including more accurate prediction of treatment response and earlier detection of resistance to the treatment). Concerning the treatment-related application, miRNAs’ mimics and antagonists (by using two main strategies of restoring tumor suppressor miRNAs and inhibiting oncogene miRNAs) have been shown to be effective therapeutic agents. However, these need to be further validated in clinical trials. Furthermore, novel delivery systems, such as lipid-based vectors, polymeric-based vectors, and exosome-based delivery, have been developed to enhance the performance of these agents. Moreover, this paper explores the current detection and measuring methods for these markers. These approaches are categorized into direct methods (e.g., Chem-NAT, HTG EdgeSeq, and Multiplex Circulating Fireplex) and indirect methods (e.g., Reverse transcription-quantitative polymerase chain reaction (RT-qPCR), qPCR, microarray, and NGS) for miRNA detection. For ctDNA measurement, main core technologies like NGS, digital PCR, real-time PCR, and mass spectrometry are suggested. © 2024 The Canadian Society of Clinical Chemists
Other Related Docs
6. Overview of Liquid Biopsy, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
7. Liquid Biopsy in Bladder Tumors, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
18. Ovarian Cancer Extracellular Vesicle Biomarkers, Clinica Chimica Acta (2025)
19. Microrna-Induced Drug Resistance in Gastric Cancer, Biomedicine and Pharmacotherapy (2015)
20. Circulating Tumor Dna (Ctdna) in the Era of Personalized Cancer Therapy, Journal of Diabetes and Metabolic Disorders (2018)